GlaxoSmithKline Plc has told shareholders of Human Genome Sciences that its $13 per share cash offer represents “full and fair value” for the company. The tender will close on 7 June. The HGS board has recommended against the offer. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
